Human Reproduction Update 2006 12(3):331; doi:10.1093/humupd/dml003
Erratum |
Errata
 |
Errata in HRU 2005; 11:545–560 |
|---|
 TOP Errata in HRU 2005;... |
|---|
The authors and the journal wish to apologise for the following errors in the paper Breast cancer risk with postmenopausal hormonal treatment. John A. Collins, Jennifer M. Blake, and Pier Giorgio Crosignani.
Page, approximate location
545: sixth last line of abstract.
. . . cancers associated with hormone use do not differ significantly from. . .
547: third last line
. . . per 10,000 women using estrogen per annum (P = 0.10, . . . delete per annum
548: third line left column
. . . four cases per 10,000 women per year, compared . . . delete per year
549: sixth line first paragraph left column
. . . per 10,000 women using EP per annum (P = 0.02, . . . delete per annum
549: third line second paragraph left column
. . . four more cases per 10,000 women per year compared . . . delete per year
549: first line of Table II footnote
delete MPA: medroxyprogesterone acetate; ND: type of HT not defined
550: fifth row of Table III
>5 years use should be 
5 years use
550: lines 9 & 10 of first full paragraph left column
Among patients using estrogen–progestin, the RRs with current or recent use were 1.15 (95% CI = 0.78–1.52, see Table III) and 1.53 (95% CI = 0.88–2.18, see Table III), respectively . . .
551: line 3 of first comment paragraph, left column
. . . is approximately 20-fold higher than in non-users. Should be 20%.
551: line 3 of second comment paragraph, left column
. . . is approximately 20% higher than in non-users. Should be 70%.
556: 2nd and 3rd lines of Table V footnote
The asterisk is P values between estrogen and estrogen-progestin exposure
The cross is P values between lobular and ductal cancers.
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||